Viewing Study NCT01203020

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 4:13 AM
Ignite Modification Date: 2026-03-31 @ 2:38 AM
Study NCT ID: NCT01203020
Status: COMPLETED
Last Update Posted: 2023-07-13
First Post: 2010-09-13
Is Gene Therapy: True
Has Adverse Events: True
Brief Title: Once Daily Targeted Intravenous (IV) Busulfex as Part of Reduced-toxicity Conditioning for Patients With Refractory Lymphomas Undergoing Allogeneic Transplantation
Sponsor: West Virginia University
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Hodgkin's Lymphoma View
None Non-Hodgkin's Lymphoma View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Hodgkin's View
None non-Hodgkin's View
None lymphomas View
None allogeneic hematopoietic progenitor cell transplant View
None HPCT View
None busulfex View
None fludarabine View
None reduced-toxicity conditioning View
None reduced-intensity conditioning View